CJC-1295 DAC: GH and IGF-1 Biomarkers and Evidence Boundaries
An evidence-led CJC-1295 DAC review focused on gh and igf-1 biomarkers, human-study limits, regulatory context and claim verification.
Review Question
This evidence review asks why hormone changes are not patient outcomes for CJC-1295 DAC. It is educational and does not provide dosing, treatment or purchasing advice.
Compound-Specific Context
CJC-1295 with a drug affinity complex is a long-acting GHRH analogue engineered to bind albumin. It must not be confused with material marketed as CJC-1295 no DAC.
The principal randomized healthy-adult publication documented multi-day exposure and sustained increases in GH and IGF-1. Its endpoints were pharmacokinetic, pharmacodynamic and short-term tolerability measures, not body composition, function, disease control or longevity.
GH and IGF-1 Biomarkers Analysis
GH and IGF-1 are useful pharmacodynamic markers, but they are surrogate measurements unless a study validates their relationship to the clinical outcome under review.
A biomarker result should be reported with timing, assay, population and comparator, then separated from claims about symptoms, function or disease.
Regulatory status, sport status and scientific evidence answer different questions and should appear in separate sentences.
Evidence Boundary Table
| Evidence layer | What this review can say |
|---|---|
| Identity | CJC-1295 with a drug affinity complex is a long-acting GHRH analogue engineered to bind albumin. It must not be confused with material marketed as CJC-1295 no DAC. |
| Human findings | The principal randomized healthy-adult publication documented multi-day exposure and sustained increases in GH and IGF-1. Its endpoints were pharmacokinetic, pharmacodynamic and short-term tolerability measures, not body composition, function, disease control or longevity. |
| Boundary | The evidence supports biological activity and prolonged exposure for the DAC molecule. It does not establish an FDA-approved indication or broad performance, recovery, weight-loss or anti-aging outcomes. |
What the Evidence Supports
The evidence supports biological activity and prolonged exposure for the DAC molecule. It does not establish an FDA-approved indication or broad performance, recovery, weight-loss or anti-aging outcomes.
- Human, animal and cell findings must be labeled separately.
- A biomarker change is not automatically a body-composition, disease or functional outcome.
- Trial authorization is not FDA approval, and historical approval does not cover a new compounded product.
- Combination claims require evidence on the combination itself.
Source-Checking Questions
- Was the exact molecule and formulation identified?
- Was the study conducted in humans, and in which population?
- Did it measure hormones, clinical outcomes or both?
- Was follow-up adequate for the safety claim?
- Does the regulatory statement apply to this product and indication?